These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 8988727

  • 21. [Preliminary results of the treatment of acute leukemia with mitoxantrone].
    Rozmysłowicz T, Pałynyczko G, Mazur J, Konecki R, Apel D, Mariańska B, Maj S, Hołowiecki J, Rudzka E, Lawniczek T.
    Acta Haematol Pol; 1991; 22(1):69-81. PubMed ID: 1823970
    [Abstract] [Full Text] [Related]

  • 22. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, Dmoszynska A, Skotnicki A, Nowak K, Holowiecki J, Polish Adult Leukemia Group.
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [Abstract] [Full Text] [Related]

  • 23. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Oct; 82(5 Suppl):19-22. PubMed ID: 9402749
    [Abstract] [Full Text] [Related]

  • 24. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
    Hiddemann W, Schleyer E, Unterhalt M, Zühlsdorf M, Rolf C, Reuter C, Kewer U, Uhrmeister C, Wörmann B, Büchner T.
    Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
    [Abstract] [Full Text] [Related]

  • 25. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA, Children's Cancer Group Study 2951.
    J Clin Oncol; 2003 Aug 01; 21(15):2940-7. PubMed ID: 12885813
    [Abstract] [Full Text] [Related]

  • 26. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
    Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W.
    Leukemia; 1998 Jul 01; 12(7):1049-55. PubMed ID: 9665189
    [Abstract] [Full Text] [Related]

  • 27. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.
    Ann Hematol; 2004 Nov 01; 83(11):696-703. PubMed ID: 15322763
    [Abstract] [Full Text] [Related]

  • 28. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Yamauchi T, Negoro E, Arai H, Ikegaya S, Takagi K, Takemura H, Inai K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Anticancer Res; 2007 Nov 01; 27(4C):2635-9. PubMed ID: 17695426
    [Abstract] [Full Text] [Related]

  • 29. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A, Polish Adult Leukemia Group.
    Eur J Haematol; 2008 Feb 01; 80(2):115-26. PubMed ID: 18076637
    [Abstract] [Full Text] [Related]

  • 30. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
    Bassan R, Chiodini B, Zucchetti M, Lerede T, Cornelli PE, Cortelazzo S, Barbui T.
    Haematologica; 1998 Jan 01; 83(1):27-33. PubMed ID: 9542320
    [Abstract] [Full Text] [Related]

  • 31. [Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
    Lemez P, Vítek A, Jelínek J, Lukásová M, Palecek A, Sajdová J, Jedlicková A, Vorlová Z.
    Vnitr Lek; 1995 Jan 01; 41(1):34-9. PubMed ID: 7716891
    [Abstract] [Full Text] [Related]

  • 32. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct 01; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 33. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul 01; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 34. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 01; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 35. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
    Martino R, Bellido M, Brunet S, Altés A, Sureda A, Guárdia R, Aventín A, Nomdedéu JF, Domingo-Albós A, Sierra J.
    Haematologica; 1999 Jun 01; 84(6):505-10. PubMed ID: 10366793
    [Abstract] [Full Text] [Related]

  • 36. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM.
    Cancer; 2004 Mar 15; 100(6):1179-85. PubMed ID: 15022284
    [Abstract] [Full Text] [Related]

  • 37. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E.
    Hematol Oncol; 2004 Jun 15; 22(2):43-53. PubMed ID: 15386563
    [Abstract] [Full Text] [Related]

  • 38. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A.
    Rev Invest Clin; 1989 Jun 15; 41(2):139-45. PubMed ID: 2675236
    [Abstract] [Full Text] [Related]

  • 39. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.
    J Clin Oncol; 2006 Sep 20; 24(27):4499-506. PubMed ID: 16983120
    [Abstract] [Full Text] [Related]

  • 40. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB.
    Jpn J Clin Oncol; 2005 Oct 20; 35(10):612-6. PubMed ID: 16172175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.